Abstract: Objective The aim of this study was to investigate tenofovir disoproxil fumarate (TDF) and compound glycyrrhizin combination therapy in patients with chronic hepatitis B (CHB). Methods 94 patients with CHB were enrolled in our hospital between June 2021 and June 2024, and were randomly assigned to receive oral TDF therapy in control (n=47), or receive oral TDF and compound glycyrrhizin combination therapy for 48 weeks. Serum HBV DNA loads were detected by PCR, serum HBeAg and HBsAg levels were assayed by electrochemiluminescence, serum HA, LN, C-IV and PC-III levels were detected by chemiluminescence, and serum IL-6, IL-8 and TNF-α were determined by ELISA. Results By end of 48-week treatment, serum HBV DNA loads became undetectable and HBeAg and HBsAg levels didn’t changed statistically differently in the two groups; serum HA, LN and PC-Ⅲ levels in the combination group were (175.2±21.9)ng/mL, (160.1±20.3)ng/mL and (147.4±18.4)ng/mL, all significantly lower than [(281.3±35.2)ng/mL, (229.4±28.7)ng/mL and (170.1±21.3)ng/mL, respectively, P<0.05] in the control; serum ALT and AST levels were (32.6±2.8)U/L and (28.4±4.1)U/L, both much lower than [(50.3±3.6)U/L and (44.2±4.3)U/L, respectively, P<0.05] in the control; serum IL-6, IL-8 and TNF-α levels were (11.8±1.5)μg/L, (4.3±1.0)μg/L and (20.6±2.6)μg/L, all much lower than [(18.1±2.3)μg/L, (6.0±1.1)μg/L and (38.1±4.8)μg/L, respectively, P<0.05] in the control group. Conclusion TDF in combination with compound glycyrrhizin in treatment of patients with CHB is efficacious, with improvement of serum liver function tests, which might be related to inhibition of liver fibrosis and reduced cytokine reactions.

Key words: Hepatitis B, Tenofovir disoproxil fumarate, Compound glycyrrhizin, Therapy